An Early Phase 1 interventional study of Cannabidiol Oil in Post-operative Pain, sponsored by Foundation for Orthopaedic Research and Education. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Foundation for Orthopaedic Research and Education · Early Phase 1, Interventional, and Treatment
insufficient drug supply at the time.
This is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications after a knee arthroscopy.
This is a prospective non-blinded randomized controlled trial with 3 groups of subjects all undergoing knee arthroscopy for soft tissue pathology. The first group will receive the SOC opioid course: 7 days of Percocet (oxycodone 5mg-acetaminophen 325mg) every four hours PO PRN, following surgery. the second 100 mg CBD daily for 30 days pre-operatively continuing 30 days post-operatively, and the third group 200 mg CBD daily for 30 days pre-operatively continuing 30 days post-operatively.
All subjects in each of the three groups will undergo standard pre-operative and post-operative care, including physical exams, imaging, and education. They will only differ in pre-operative pain medication administration if they are in one of the two CBD groups. The groups will undergo surveys (sleep quality, self-reported pain, need for refill or switch to opioids). Sleep quality will be assessed with the Insomnia Severity Index (ISI) while pain, need for refill, and switch to opioids will be recorded by the patient on CRF packets. The CRF packets will be given to patients at each visit for them to fill out to the best of their ability.
5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.
Browse Pain, Postoperative studies →Foundation for Orthopaedic Research and Education is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Opioid standard of care: Percocet (oxycodone 5mg-acetaminophen 325 mg) every 4 hours PRN postoperatively for 7 days
CDB 100mg PO liquid suspension QD starting 30 days prior to surgery and finishing 30 days post-operatively
Drug: Cannabidiol Oil
CBD 200mg PO liquid suspension QD starting 30 days prior to surgery and finishing 30 days post-operatively.
Drug: Cannabidiol Oil
Subjects will self administer CBD sublingually
Post-operative pain control
Numerical Pain Scale (NRS) 0 being no pain, 10 being the worst pain imaginable.
Time frame: 30 days post-operatively
Sleep Quality
Insomnia Severity Index .
Time frame: 30 days preoperatively leading up to surgery, then 30 days postoperatively. Outcomes will be collected from surgery to 6 weeks postoperatively.
insufficient drug supply at the time.
insufficient drug supply at the time.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Foundation for Orthopaedic Research and Education